Financial statements NOTES TO THE COMPANY FINANCIAL STATEMENTS 42.
ADOPTION OF NEW AND REVISED STANDARDS The impact on the Company of new and revised standards is the same as for the Group.
Details are given in Note 1 to the consolidated financial statements.
SIGNIFICANT ACCOUNTING POLICIES The separate financial statements of the Company are presented as required by the Companies Act 2006.
As permitted by that Act, theseparate financial statements have been prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board IASB.
The financial statements have also been prepared in accordance with IFRSs adopted foruse in the European Union and UK company law.
The financial statements have been prepared on the historical cost basis.
The principal accounting policies adopted are the same as those setout in Note 2 to the consolidated financial statements with the addition of the policies noted below.
Investments in subsidiaries are stated at cost less, where appropriate, provisions for impairment.
Equity-settled employee share schemes are accounted for in accordance with IFRIC 11 Group and Treasury Share Transactions, whereby current charge expenses relating to the subsidiaries employees are recharged to subsidiary companies.
INVESTMENTS IN SUBSIDIARIES Investments in subsidiaries represent the following: Ownership % Ownership % Ordinary shares Ordinary shares Companys name Established in 2014 2013 Hikma Limited UK 100 100 Hikma Pharma Limited Jersey 100 100 Hikma Acquisitions UK Limited UK 100 100 Al Jazeera Pharmaceutical Industries Ltd KSA 52.5 52.5 Hikma Pharmaceuticals Limited Jordan 22.8 Hikma MENA Holdings UAE 100 100 AMKI MENA Holdings UAE 100 100 Hikma International NV Netherlands 100 100 Eurohealth International SARL Switzerland 100 Hikma Finance Luxembourg SARL Luxembourg 100 The investments in subsidiaries are all stated at cost.
The remaining shares are held by other Group companies 45.
DUE FROM SUBSIDIARIES AND SISTER COMPANIES 2014 2013 Non-current assets $m $m West-Ward Pharmaceuticals Corp. 74 50 Hikma Italia S. p. A 4 4 Hikma MENA Holdings 18 Hikma International Pharmaceuticals 7 Eurohealth International SARL 46 149 54 These balances represent loans that carry interest of 2.0% to 4.8% 2013: 2.0% to 4.8% per annum charged on the outstanding loan balances.
2014 2013 Current assets $m $m Due from Hikma Farmacutica Portugal 1 1 Due from Hikma UK Limited 56 74 Due from Hikma Limited UK 1 1 Due from Hikma MENA Holdings 23 13 Due from West-Ward Pharmaceuticals Corp. 1 1 Due from Hikma Pharmaceuticals Limited Jordan 39 Others 3 2 85 131 167
